What does the company do?
The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of medicines to the worldwide hospital marketplace. The Company has two marketed products, Angiomax (bivalirudin) and Cleviprex (clevidipine butyrate) injectable emulsion, two products in late-stage development, cangrelor and oritavancin, which the Company acquired in February 2009, and one compound, CU-2010, scheduled to enter clinical development during 2009.
How much does the company sell and earn?
Investors need to know how much stuff or services a company sells, and how much of that total it keeps as income (or profit) to grow its business or return to shareholders. The more of each, the better. In general, look for companies that sell and earn more than peers.
- Medicines one-year sales: 396.05 Mil.
Difference from the average for the Drug Manufacturers - Other group: -94.54% - Medicines one-year income: -6.93 Mil.
| Sales & Income (past 12 months) | Company | Industry |
|---|
| Sales | 396.05 Mil | 7.25 Bil | | Income | -6.93 Mil | 926.18 Mil |
How fast is the company growing?
- Medicines one-year sales growth: 18.80%.
Difference from the average for the Drug Manufacturers - Other group: -7.10 pct. pts.| Sales & Income Growth (past 12 months) | Company | Industry |
|---|
| Sales Growth | 18.80% | 25.90% | | Income Growth | NA | 144.30% |
How profitable is the company?
Investors prefer companies that increase profit margins -- the percentage of sales that they keep -- every year. This is accomplished either by lowering expenses or raising prices. Look for companies that consistently find ways to squeeze more profits out of sales than their peers.
- Medicines one-year net profit margin: -1.8%
Difference from the average for the Drug Manufacturers - Other group: 18.3 pct. pts.
| Net profit margins (%) |
|---|
| Company | -1.8% | | Company 5-Yr Avg. | 4.1% | | Industry | -20.0% |
How is the company's financial health?
The debt/equity ratio shows how much a firm has borrowed as a percentage of its stock equity. The lower, the better.
- Medicines debt/equity ratio: 0.00.
Average debt/equity ratio for the Drug Manufacturers - Other group: 0.28.
| | Company | Industry |
|---|
| Debt/equity ratio | 0.00 | 0.28 |
|
Recent News